Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors at 8 institutions in 1 country.
Iris A S StrootDepartment of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID 0000-0002-5506-8841
Jan BrouwerDepartment of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Joost BartDepartment of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID 0000-0002-0985-071X
Harry HollemaDepartment of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Denise J Stommel-JennerDepartment of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Marise M WagnerDepartment of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Helena C van DoornDepartment of Gynecologic Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.ORCID 0000-0003-1062-4485
Joanne A de HulluDepartment of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, the Netherlands.
Katja N GaarenstroomDepartment of Obstetrics and Gynecology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-4702-1680
Marc BeurdenDepartment of Gynecology, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
Luc R C W van LonkhuijzenDepartment of Gynecologic Oncology, Amsterdam University Medical Center-Center for Gynecological Oncology Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0001-6905-2704
Brigitte F M SlangenDepartment of Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands.
Ronald P ZweemerDepartment of Gynecologic Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-1829-7773
Encarna B Gómez GarciaDepartment of Clinical Genetics, University Medical Center Maastricht, Maastricht, the Netherlands.ORCID 0000-0003-4999-8847
Margreet G E M AusemsDivision Laboratories, Pharmacy and Biomedical Genetics, Department of Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.ORCID 0000-0003-0305-3477
Ingrid A BoereDepartment of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Klaartje van EngelenDepartment of Human Genetics, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Christi J van AsperenDepartment of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-1436-7650
Marjanka K SchmidtDepartment of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-2228-429X
Marijke R WeversDepartment of Clinical Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID 0000-0001-8008-6008
Geertruida H de BockDepartment of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID 0000-0003-3104-4471
Marian J E MouritsDepartment of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.ORCID 0000-0003-2385-2639
HEBON Investigators
University Medical Center Groningen · NLLeiden University Medical Center · NLErasmus MC Cancer Institute · NLMaastricht University · NLRadboud University Nijmegen · NLUniversity Medical Center Utrecht · NLThe Netherlands Cancer Institute · NLVrije Universiteit Amsterdam · NL
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
purposeTo investigate the prevalence of and clinical factors associated with high-grade serous carcinoma (HGSC) at risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic PATIENTS AND
methodsWe included
resultsOf the 2,557 included women, 1,624 had
conclusionWe detected HGSC in 1.5% (
Indexed as
CarcinomaFallopian Tube NeoplasmsOvarian NeoplasmsBRCA1 ProteinBRCA2 ProteinFemaleGenetic Predisposition to DiseaseHumansMutationOvariectomyPrevalenceSalpingo-oophorectomyBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of · full record | OpenQuestion